On March 18, Shanghai Pharmaceuticals announced that its subsidiary, Shanghai Shangyao Xinya Pharmaceutical Co., Ltd., recently received the "Approval Notice for Supplementary Drug Application" issued by the National Medical Products Administration for its cefazolin sodium for injection, indicating that the drug has passed the consistency evaluation of generic drug quality and efficacy.

According to reports, cefazolin sodium for injection is indicated for the treatment of respiratory tract infections, urinary tract infections, skin and soft tissue infections, bone and joint infections, sepsis, infective endocarditis, hepatobiliary system infections, reproductive system infections, and perioperative infection prevention caused by susceptible bacteria. In July 2024, Shanghai Pharmaceuticals New Asia submitted an application to the National Medical Products Administration for consistency evaluation of generic versions of this drug, which was accepted.

Shanghai Pharmaceuticals stated that products that pass the consistency evaluation will receive greater support in areas such as medical insurance reimbursement and procurement by medical institutions. Therefore, the successful completion of the generic drug consistency evaluation for Shanghai Pharmaceuticals New Asia's cefazolin sodium for injection will help expand the drug's market share and enhance its market competitiveness. At the same time, it provides valuable experience for the company's subsequent consistency evaluation work.

https://finance.eastmoney.com/a/202603183675924554.html